Filing search / Kineta, Inc. / "Leadership"

8-K

EX-99.1

KANT Kineta, Inc.

5 Jan 24

Regulation FD Disclosure

4:30pm

Investor Relations & Business Development Experienced leadership team Craig Philips President Keith Baker Chief Financial Officer Pauline Kenny General

8-K

EX-99.2

KANT Kineta, Inc.

6 Nov 23

Kineta Unveils Positive New Data from VISTA-101 Clinical Trial of KVA12123 at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting

8:30am

& Business Development Experienced leadership team Craig Philips President Keith Baker Chief Financial Officer Pauline Kenny General Counsel KVA12123

8-K

EX-99.2

KANT Kineta, Inc.

17 Oct 23

Entry into a Material Definitive Agreement

8:32am

Scientific Officer Jacques Bouchy EVP Investor Relations & Business Development Experienced leadership team Craig Philips President Keith Baker Chief

8-K

EX-99.1

giup65e2tkz

11 Aug 23

Regulation FD Disclosure

4:08pm

8-K

EX-99.1

gjmf9

9 Jun 23

Submission of Matters to a Vote of Security Holders

9:00am

8-K

EX-99.1

x4pwor g5jzt

31 Mar 23

Regulation FD Disclosure

12:00am

8-K

EX-99.5

b9kadgjk ojxt85p

22 Dec 22

Kineta Completes Reverse Merger with Yumanity Therapeutics

5:02pm

8-K

i88tcw

22 Dec 22

Kineta Completes Reverse Merger with Yumanity Therapeutics

5:02pm

425

pw24q52yq0 v9lcui

6 Dec 22

Business combination disclosure

4:04pm

8-K

EX-99.1

fgu1rq o7

6 Dec 22

Regulation FD Disclosure

4:02pm

424B3

3jekkvyznpfu2c2 p3

10 Nov 22

Prospectus supplement

4:21pm

425

pw77s

26 Oct 22

Business combination disclosure

5:17pm

8-K

EX-99.1

l2jmeeqv3

26 Oct 22

Regulation FD Disclosure

5:14pm